View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
November 2, 2021

Coronavirus company news summary – Indonesia grants emergency approval to Novavax vaccine – Resverlogix in talks to start Covid-19 treatment trial in Morocco

By Chris Lo

The National Agency of Drug and Food Control of the Republic of Indonesia has granted Emergency Use Authorization (EUA) to Novavax’s Covid-19 vaccine. Serum Institute of India will produce the vaccine in India and market it under the brand name COVOVAX in Indonesia. The first shipments of the recombinant nanoparticle protein-based vaccine with Matrix-M adjuvant into Indonesia are planned to commence shortly. The companies have also sought authorisation for the vaccine in India and the Philippines, as well as emergency listing with the World Health Organization.

Resverlogix has reported that the company is holding talks with the Ministry of Health of the Kingdom of Morocco to commence Phase II clinical trials of its epigenetic drug, apabetalone, to treat Covid-19. The company is engaging with hospitals as well as health ministries of several other countries to launch Covid-19 trials. It has received clearance from Health Canada to conduct trials. Pending final protocol clearance, a Phase III trial is expected to begin in the following months in the US.

The Health Ministry of Zimbabwe has granted approval for Sinovac Biotech’s Covid-19 vaccine in individuals aged 16-17 years. The country aims to achieve herd immunity by the end of 2021, Reuters reported. The Sinovac vaccine is the only one in the country indicated for use in this age group. All the provinces, secondary schools, universities, colleges, and vaccination sites in the country have been instructed to start inoculating adolescents of this age.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU